Navigation Links
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Date:1/17/2008

lly in patients with DBCL are also encouraging".

About ZEVALIN(R)

ZEVALIN(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 ZEVALIN administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the ZEVALIN therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to ZEVALIN therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). ZEVALIN should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results.
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
2. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
3. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... MOUNTAIN VIEW, Calif. , Oct. 22, ... 11:00 a.m. EDTLOCATION: Online, complimentary registration available ... Group Team Leader Archana Vidyasekar and Visionary ... VargheseBrain-controlled computers, WiFi-like wireless electricity, self-assembling materials, ... top ten technologies which will transform our ...
(Date:10/22/2014)... 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... IAP310 study have been published in Regional ... journal with broad, multidisciplinary readership. IAP310 was a ... and efficacy of Zalviso, also referred to as ... treatment of post-operative pain in patients following open ...
(Date:10/22/2014)... CAMBRIDGE, Mass. and SHANGHAI ... Inc. (NASDAQ: FMI ) and WuXi ... announced a collaboration to offer Foundation Medicine,s comprehensive genomic ... China . Under the ... enable WuXi to perform the laboratory component of Foundation ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... Inc. (Inspiration) announced today that the European Commission has ... of hemophilia.  Expected to enter pivotal clinical trials before ... treat individuals with hemophilia who have developed inhibitors against ... trigger a 10-year market exclusivity for OBI-1 in the ...
... DIEGO, Oct. 19 Aethlon Medical, Inc. (OTC Bulletin ... therapeutic filtration devices to address infectious disease and cancer, ... the Aethlon Medical board of directors. ... ) Mr. Kenley has 33 years of ...
Cached Medicine Technology:Inspiration Biopharmaceuticals' OBI-1 Receives Orphan Drug Designation in Europe 2Inspiration Biopharmaceuticals' OBI-1 Receives Orphan Drug Designation in Europe 3Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 2Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 3Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 4Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 5
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute ... to repair a damaged mitral valve as the heart ... developed by Abbott Vascular , is designed to ... condition in which the heart’s mitral valve leaflets fail ... the heart’s left ventricle into the left atrium. The ...
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
Breaking Medicine News(10 mins):Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... , WEDNESDAY, July 20 (HealthDay News) -- Premature ... as teenagers, including attention deficit hyperactivity and depression, a ... the result of brain injuries affecting cortical development as ... Columbia University Medical Center. Although "preemies" are at ...
... In the fight to improve global health, alleviate hunger, ... world, chickens have an important role to play. ... for Infectious Diseases and Vaccinology at Arizona State University,s ... more productive species of chicken for villagers in rural ...
... of Minnesota Medical School researchers have developed a new strategy ... Currently, iPS cells are created by introducing four defined ... cell into a stem cell, which can differentiate into many ... four genes introduced are Oct4, Sox2, Klf4 and c-Myc, a ...
... dramatically among young people, it is deadly if not caught ... adapt to even the most modern therapies, known as VEGF ... discovery about proteins that underlie and stimulate the disease, opening ... This month in the journal Cancer Research , ...
... BOSTON Beth Israel Deaconess Medical Center (BIDMC) has ... Allergy and Infectious Diseases (NIAID), part of the National ... Vaccine Research in Nonhuman Primates. The five-year grant totals ... H. Barouch, MD, PhD, a Professor of Medicine at ...
... Bristol-Myers Squibb Company announced results from a long-term, ... (ARV)-experienced patients (336 female and 958 male) from ... at the Sixth International AIDS Society Conference on ... In a gender-specific sub-analysis, boosted REYATAZ (atazanavir sulphate) ...
Cached Medicine News:Health News:Preemies at Risk for Psychiatric Disorders as Teens, Study Contends 2Health News:A new breed: Highly productive chickens help raise Ugandans from poverty 2Health News:A new breed: Highly productive chickens help raise Ugandans from poverty 3Health News:U of M researchers improve method to create induced pluripotent stem cells 2Health News:URMC researchers exploring keys to melanoma progression 2Health News:URMC researchers exploring keys to melanoma progression 3Health News:In the real life setting, boosted REYATAZ proves as effective in women living with HIV as men 2
... Merocel Ophthalmic Products ... superior fiber free products ... and safe cleaning of ... exclusive Merocel material is ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
Weck-Cel Triangle shaped spearhead, set on a malleable, polypropylene handle, is designed for use in delicate, surgical areas. Maintains rigidity during wicking process. Single use, packaged sterile....
Medicine Products: